Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VY-AADC01 in Parkinson's disease
NCT03065192Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- May 2017
- Primary completion
- Aug 2021
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ezaladcigene resoparvovec in Parkinson's disease (PD), sponsored by Neurocrine Biosciences. Primary endpoints: Adverse Events at 3 years, Magnetic Resonance Imaging at 3 years and 3 more. Started May 2017; status: completed.
02
Drugs
ezaladcigene resoparvovec
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03065192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03065192.